Abstract
Objective Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder that leads to increasing muscle weakening and early death. Steroids, the standard treatment of choice in slowing down disease progression, are plagued with adverse effects. Following anti-inflammatory and anti-fibrotic outcomes of an Aureobasidium pullulans strain N-163-produced beta 1,3-1,6-glucan food supplement in clinical and pre-clinical studies of DMD, herein we report their implications on the gut microbiome in patients with DMD.
Design Twenty-seven patients with DMD were included in the pilot study (Control [n=9], N-163 [n=18]) which had previously reported the clinical decrease in inflammatory and fibrosis biomarkers. For the current study, whole genome metagenomic sequencing was performed in pre- and post N-163 intervention faecal samples of each of these participants.
Results After N-163 beta-glucan administration, the constitution of the gut microbiome in all the participants was modified to one with positive outcomes on health. There was an increase in butyrate-producing species such as Roseburia and Faecalibacterium prausnitzii. There was a decrease in harmful bacteria associated with inflammation such as enterobacteria and Alistipes.
Conclusion Beneficial reconstitution of the gut microbiome after N-163 beta-glucan administration, in addition to their implications in anti-inflammatory and anti-fibrotic outcomes, require further in-depth exploration on their roles in epigenetic manipulation.
Competing Interest Statement
Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and an applicant to several patents of relevance to these beta glucans.
Clinical Trial
CTRI/2021/05/033346
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
drkraghavan{at}nichimail.jp, drddp{at}nichimail.jp, lb-20yamamoto{at}hospk.ncgm.go.jp, nikewaki{at}phoenix.ac.jp, miwasaki{at}yamanashi.ac.jp, adinassing{at}govmu.org, rsk{at}nichimail.jp, drspp{at}nichimail.jp, drsam{at}nichimail.jp
Declarations
Ethics approval and consent to participate The study was registered in Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5th May, 2021. The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.
Consent for publication Not applicable
Availability of data and material All data generated or analysed during this study are included in the article itself.
Funding No external funding was received for the study
Competing interests Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and an applicant to several patents of relevance to these beta glucans.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos